Nurix presents the discovery and chemical structure of first-in-class cbl-b inhibitor nx-1607 at the american chemical society (acs) meeting

Presentation highlights nurix's innovation and leadership in targeted protein modulation, including ligase inhibition unique mechanism of action, an intramolecular glue, locks the e3 ligase casitas b-lineage lymphoma proto-oncogene b (cbl-b) in a closed inactive state phase 1 trial ongoing as monotherapy and in combination with paclitaxel in patients with a range of oncology indications san francisco, march 20, 2024 (globe newswire) -- nurix therapeutics, inc. (nasdaq: nrix), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today disclosed the discovery and structure of nx-1607 in the first time disclosures session at the american chemical society spring 2024 meeting in new orleans, la. this is the first inhibitor of cbl-b to advance into clinical studies and a prime example of nurix's ability to target previously undruggable e3 ligases.
NRIX Ratings Summary
NRIX Quant Ranking